Stoke Current Deferred Revenue from 2010 to 2026
| STOK Stock | USD 31.91 0.02 0.06% |
Current Deferred Revenue | First Reported 2020-03-31 | Previous Quarter 8.7 M | Current Value 5.8 M | Quarterly Volatility 7.9 M |
Check Stoke Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Stoke Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 15.3 M, Interest Income of 131.1 K or Discontinued Operations of 0.0, as well as many indicators such as Price To Sales Ratio of 26.26, Dividend Yield of 0.0 or PTB Ratio of 2.46. Stoke financial statements analysis is a perfect complement when working with Stoke Therapeutics Valuation or Volatility modules.
Stoke | Current Deferred Revenue | Build AI portfolio with Stoke Stock |
Historical Current Deferred Revenue data for Stoke Therapeutics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Stoke Therapeutics represents a compelling investment opportunity.
Latest Stoke Therapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Stoke Therapeutics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Stoke Therapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Stoke Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Stoke Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 4,674,134 | |
| Coefficient Of Variation | 219.54 | |
| Mean Deviation | 9,248,644 | |
| Median | (1,066,000) | |
| Standard Deviation | 10,261,387 | |
| Sample Variance | 105.3T | |
| Range | 25.9M | |
| R-Value | 0.88 | |
| Mean Square Error | 25.4T | |
| R-Squared | 0.77 | |
| Slope | 1,787,413 | |
| Total Sum of Squares | 1684.7T |
Stoke Current Deferred Revenue History
About Stoke Therapeutics Financial Statements
Stoke Therapeutics investors utilize fundamental indicators, such as Current Deferred Revenue, to predict how Stoke Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 21.8 M | 22.9 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Stoke Therapeutics Correlation against competitors. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Stoke Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share 0.68 | Revenue Per Share | Quarterly Revenue Growth 1.172 | Return On Assets | Return On Equity |
Investors evaluate Stoke Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Stoke Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Stoke Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Stoke Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.